Cellebrite DI (CLBT) Liabilities and Shareholders Equity (2020 - 2026)

Cellebrite DI's Liabilities and Shareholders Equity history runs 6 years deep, the most recent figure standing at $938.9 million for Q4 2025.

• In Q4 2025, Liabilities and Shareholders Equity rose 35.95% year-over-year to $938.9 million; the TTM figure through Dec 2025 stood at $3.3 billion (up 35.96% YoY), while the FY2025 annual figure was $938.9 million, up 35.95% from the prior year.
• Liabilities and Shareholders Equity for Q4 2025 stood at $938.9 million, up from $834.3 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $938.9 million in Q4 2025, with the low at $221000.0 in Q2 2022.
• The 5-year median for Liabilities and Shareholders Equity is $503.0 million (2023), against an average of $514.4 million.
• The sharpest annual moves came in 2021 and 2023: Liabilities and Shareholders Equity slipped 6.75% in 2021, then surged 192611.76% in 2023.
• Cellebrite DI's Liabilities and Shareholders Equity stood at $339.8 million in 2021, then advanced by 18.69% to $403.3 million in 2022, then surged by 32.13% to $532.9 million in 2023, then advanced by 29.59% to $690.6 million in 2024, then soared by 35.95% to $938.9 million in 2025.
• Business Quant data shows CLBT's Liabilities and Shareholders Equity at $938.9 million in Q4 2025, $834.3 million in Q3 2025, and $787.4 million in Q2 2025.